Affiliation:
1. I.M. Sechenov First Moscow State Medical University
Abstract
The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome. Telmisartan is second-generation type 1 angiotensin II receptor blocker, which has unique pleiotropic effects due to partial affinity for receptors that activate the proliferation of subtype y peroxisomes (PPARy) located in adipose tissue. The interrelation of metaflamation, a specific chronic inflammatory process with pathogenetic mechanisms of development of cardiovascular diseases, including arterial hypertension, is also described in study. The role of the adiponectin peptide is considered, which synthesis is stimulated by partial PPARy receptor agonists (as mentioned above — telmisartan). It has a positive effect on fat and carbohydrate metabolism, as well as cardioprotective properties. The conclusion contains the results of numerous randomized studies and meta-analyzes confirming the high efficacy of telmisartan in the treatment of arterial hypertension in patients with morbid obesity.
Subject
Cardiology and Cardiovascular Medicine
Reference42 articles.
1. Romantsova TI. Obesity Epidemic: obvious and probable causes. Obesity and metabolism. 2014;1:5-19. (In Russ.) Романцова Т. И. Эпидемия ожирения: очевидные и вероятные причины. Ожирение и метаболизм. 2014;1:5-19.
2. Hales CM, Fryar CD, Carroll MD, et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723-5. doi:10.1001/jama.2018.3060.
3. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief. 2017;Oct(288):1-8.
4. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369-81. doi :10.1016/j.pcad.2013.10.016.
5. Dombrovskiy VS, Khachatryan GR. Comparison of recommended screening programs in the United States, Сanada, the Netherlands and Germany. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016;4:46-53 (In Russ.) doi:10.17749/2070-4909.2016.9.4.046-053.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献